

**REMARKS**

Upon entry of the above amendments, claims 1 to 33, 35, and 42 to 46 are pending. Claims 34, and 36 to 41 have been cancelled. Claims 35 and 42 have been amended. New claims 44 to 46 have been added. Support for the new claims can be found in the specification as originally filed. See, for example, page 10 line 30 through page 12 line 29 of the specification, and pages 78 to 85 of the claims as originally filed. Applicants have amended the claims to place them in a form appropriate for U.S. practice, and to reduce the filing fee by, *inter alia*, removing multiple dependencies. Applicants have amended the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper in accordance with U.S. practice.

Respectfully submitted,



Jennifer L. Fox  
Agent for Applicant  
Registration No. 52,218

Date: 8 December 05  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-6334  
Facsimile: 919-483-7988